NameDescription
Assigned female at birth
Cisgender women and all other persons assigned female at birth (including transgender men and nonbinary persons).
Sex assigned at birth = female
OR
Sex assigned at birth missing or unknown AND administrative gender = female
OR
gender identity = transgender male
Current breast cancer
Currently diagnosed with invasive or non-invasive breast cancer without having achieved remission.
CONDITIONS include `BREAST CANCER` with status active
History of bilateral mastectomy
Past history of bilateral mastectomy or unilateral mastectomy on both sides.
CONDITIONS include `BILATERAL MASTECTOMY` OR PROCEDURES include `BILATERAL MASTECTOMY PROCEDURE`
OR
(CONDITIONS include `LEFT UNILATERAL MASTECTOMY` OR PROCEDURES include `LEFT UNILATERAL MASTECTOMY PROCEDURE`
AND
CONDITIONS include `RIGHT UNILATERAL MASTECTOMY` OR PROCEDURES include `RIGHT UNILATERAL MASTECTOMY PROCEDURE`
Breast symptoms
Patient reported symptoms concerning for breast disease.
REVIEW OF SYMPTOMS include `BREAST-RELATED SIGNS OR SYMPTOMS`
Breast exam findings
Physical exam findings concerning for breast disease.
PHYSICAL EXAM OBSERVATIONS include `BREAST-RELATED SIGNS OR SYMPTOMS`
Patient eligible for screening
Patient determined to be eligible for screening.
See 'Screening Eligible' flow logic
Genetic marker or syndrome associated with a high risk of breast cancer
Genetic marker or syndrome associated with a high risk of breast cancer (e.g., BRCA1 or BRCA2 genetic variation).
CONDITIONS include `GENETIC SUSCEPTIBILITY FOR BREAST CANCER` with status active
OR
Structured documentation of `GENETIC MARKER OR SYNDROME`
Genetic marker or syndrome associated with a high risk of breast cancer as defined by ACS
ACS defined genetic marker or syndrome associated with a high risk of breast cancer, including BRCA1 or BRCA2, Li-Fraumeni syndrome (TP53 gene), Cowden or Bannayan-Riley-Ruvalcaba syndrome (PTEN gene)
CONDITIONS include `BRCA-1 MUTATION CONDITION`
OR
CONDITIONS include `BRCA-2 MUTATION CONDITION`
OR
CONDITIONS include `LI-FRAUMENI SYNDROME`
OR
CONDITIONS include `COWDEN SYNDROME`
OR
CONDITIONS include `BANNAYAN-RILEY-RUVALCABA SYNDROME`
Untested first-degree relative of BRCA carrier
First-degree relative of BRCA carrier, but untested
FAMILY HISTORY of brca1 or brca2 in first degree relative, including parent or child
First-degree relative of Li-Fraumeni syndrome, Cowden or Bannayan-Riley-Ruvalcaba syndrome
First degree relative with Li-Fraumeni syndrome (TP53 gene), Cowden or Bannayan-Riley-Ruvalcaba syndrome (PTEN gene)
FAMILY HISTORY of Li-Fraumeni syndrome, Cowden or Bannayan-Riley-Ruvalcaba syndrome in first degree relative, including parent or child
History of high-dose radiation therapy to the chest
History of high-dose radiation therapy to the chest at a young age.
CONDITIONS include `CHEST RADIOTHERAPY` with age of onset <= 30 years
Previous breast cancer
Past history of invasive or non-invasive breast cancer, with remission.
CONDITIONS include `BREAST CANCER` with status inactive, resolved, remission
OR
CONDITIONS include `PREVIOUS BREAST CANCER` with status active
High-risk benign breast lesion on previous biopsies
Past high-risk benign histology on breast biopsy at any time. Includes Atypical ductal hyperplasia (ADH) and lobular neoplasia (lobular carcinoma in situ [LCIS]/atypical lobular hyperplasia [ALH]).
CONDITIONS or DIAGNOSIS CODES include `ATYPICAL HYPERPLASIA`, `ATYPICAL DUCTAL HYPERPLASIA`, `ATYPICAL LOBULAR HYPERPLASIA`, `LOBULAR CARCINOMA IN SITU`
OR
PATHOLOGY REPORT of type `BREAST BIOPSY` includes narrative documentation of pre-malignant or high-risk lesions
Lifetime risk of breast cancer > 20% or 25%
Have a lifetime risk of breast cancer of about 20% to 25% or greater, according to risk assessment tools that are based mainly on family history
Risk assessment using a formal risk assessment tool based mainly on family history is >20% lifetime risk
OR
Risk assessment without using a formal tool is estimated >20% lifetime risk
BI-RADS breast density category C or D
Heterogeneously or extremely dense breast on mammography
BI-RADS breast density category of 'Last mammography', as reported in DIAGNOSTIC REPORT or documented in a structured form
Indicators of reduced life expectancy
Criteria that may indicate reduced life expectancy.
Patient receiving Hospice Services
Hospice services used by patient during the measurement period.
CONDITIONS or ENCOUNTER DIAGNOSES include codes from `HOSPICE INTERVENTION` OR `HOSPICE ENCOUNTER`
Patient receiving Palliative Care Services
Palliative care services used by patient during the measurement period.
CONDITIONS or ENCOUNTER DIAGNOSES include codes from `PALLIATIVE INTERVENTION` OR `PALLIATIVE ENCOUNTER`
Patient age 66 or older in Institutional Special Needs Plans or residing in long-term care facility
Patients age 66 or older in Institutional Special Needs Plans (SNP) or residing in long term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period.
AGE >= 66 years
AND
ENCOUNTER DIAGNOSES with POS code 32, 33, 34, 54 or 56 for more than 90 consecutive days
Patient with Frailty AND Medication for Dementia
Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period AND a dispensed medication for dementia during the measurement period or the year prior to the measurement period.
AGE >= 66 years
AND
>= 1 ENCOUNTER DIAGNOSES include `CODES TO IDENTIFY FRAILTY`
AND
>= 1 MEDICATIONS include `DEMENTIA EXCLUSION MEDICATIONS` with dispense
Patient with Frailty AND Advanced Illness
Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period.
AGE >= 66 years
AND
>= 1 ENCOUNTER DIAGNOSES include `CODES TO IDENTIFY FRAILTY`
AND
(>= 1 ENCOUNTER of type acute inpatient where DIAGNOSES include `CODES TO IDENTIFY ADVANCED ILLNESS` OR >= 2 ENCOUNTERS of type outpatient, observation, ED or nonacute inpatient where DIAGNOSES include `CODES TO IDENTIFY ADVANCED ILLNESS`)
Last mammography
Latest mammography, screening or diagnostic, including film, digital or digital breast tomosynthesis (3D) mammography. Can be determined from presence of radiology report or result documented in a structured form.
Latest DIAGNOSTIC REPORT of type `SCREENING MAMMOGRAPHY` OR `DIAGNOSTIC MAMMOGRAPHY`
OR
Documented result of latest `SCREENING MAMMOGRAPHY` OR `DIAGNOSTIC MAMMOGRAPHY`.
Date of last mammography
Date of latest mammography.
Study date of 'Last mammography'
Last mammography result
BI-RADS score of 'Last mammography', as reported in DIAGNOSTIC REPORT or documented in a structured form
Pending mammography
Patient has an active mammography order or referral.
Most recent ORDER or REFERRAL with exam code `SCREENING MAMMOGRAPHY` AND status is active
Last MRI
Latest MRI, screening or diagnostic. Can be determined from presence of radiology report or result documented in a structured form.
Latest DIAGNOSTIC REPORT of type `SCREENING MRI`
OR
Documented result of latest `SCREENING MRI` as BI-RADS score.
Date of last MRI
Date of latest MRI.
Study date of 'Last MRI'
Last MRI result
BI-RADS score of 'Last MRI', as reported in DIAGNOSTIC REPORT or documented in a structured form
Pending MRI
Patient has an active MRI order or referral.
Most recent ORDER or REFERRAL with exam code `SCREENING MRI` AND status is active
Last ultrasound
Latest US, screening or diagnostic. Can be determined from presence of radiology report or result documented in a structured form.
Latest DIAGNOSTIC REPORT of type `SCREENING US` OR `DIAGNOSTIC US`
OR
Documented result of latest `SCREENING US` OR `DIAGNOSTIC US` as BI-RADS score.
Date of last ultrasound
Date of latest ultrasound.
Study date of 'Last ultrasound'
Pending ultrasound
Patient has an active MRI order or referral.
Most recent ORDER or REFERRAL with exam code `SCREENING US` AND status is active
Last biopsy
Latest breast biopsy. Can be determined from presence of pathology report or result documented in a structured form.
Latest DIAGNOSTIC REPORT of type `BREAST BIOPSY`
OR
Documented result of latest `BREAST BIOPSY` as diagnostic code.
Date of last biopsy
Date of latest biopsy.
Study date of 'Last biopsy'
Pending biopsy
Patient has an active biopsy order or referral.
Most recent ORDER or REFERRAL where exam code is `BREAST BIOPSY PROCEDURE` AND status is active
Biopsy result negative
Pathology of breast biopsy has no atypical hyperplasia, LCIS or malignant findings and is not indeterminate or discordant. May have other benign breast conditions.
Biopsy result atypical
Pathology of breast biopsy has atypical findings.
Biopsy result indeterminate
Pathology of breast biopsy has indeterminate findings.
Biopsy result is `INDETERMINATE HISTOLOGY`
Biopsy result discordant
Pathology of breast biopsy has findings discordant with imaging result.
Biopsy result is 'Biopsy result negative' AND 'Last mammography result' is BI-RADS 5
Biopsy result malignant
Pathology of breast biopsy has malignant findings.
Biopsy result includes `INVASIVE BREAST CANCER` OR `NON-INVASIVE BREAST CANCER`
BRCA-1 mutation test
BRCA-1 mutation diagnostic test, including pathology report
EXISTS DIAGNOSTIC TEST with type `BRCA-1 MUTATION`
BRCA-2 mutation test
BRCA-2 mutation diagnostic test, including pathology report
EXISTS DIAGNOSTIC TEST with type `BRCA-2 MUTATION`
BRCA-1 mutation diagnosis
Known BRCA-1 mutation carrier.
CONDITIONS include `BRCA-1 MUTATION CONDITION` with status active
BRCA-2 mutation diagnosis
Known BRCA-2 mutation carrier.
CONDITIONS include `BRCA-2 MUTATION CONDITION` with status active
Family history of known BRCA1/2 mutation
Family member with known BRCA mutation of any type.
FAMILY HISTORY includes family member with DIAGNOSIS `BRCA-1 MUTATION CONDITION` OR `BRCA-2 MUTATION CONDITION`
Family history of breast cancer
Family history of breast cancer.
FAMILY HISTORY includes family member with DIAGNOSIS `INVASIVE BREAST CANCER`
OR
FAMILY HISTORY includes family member with DIAGNOSIS `NON-INVASIVE BREAST CANCER`
Family history of ovarian cancer
Family history of ovarian cancer.
FAMILY HISTORY includes family member with DIAGNOSIS `OVARIAN CANCER`
Family history of tubal cancer
Family history of tubal cancer.
FAMILY HISTORY includes family member with DIAGNOSIS `TUBAL CANCER`
Family history of peritoneal cancer
Family history of peritoneal cancer.
FAMILY HISTORY includes family member with DIAGNOSIS `PERITONEAL CANCER`
'Compelling family history of breast cancer' is true
Pedigree of blood relatives on maternal and/or paternal side includes compelling history of breast cancer.
Output of validated brief familial risk assessment tool is positive
OR
'Informal familial risk criteria' exist
Informal familial risk criteria
Criteria in first- or second-degree blood relatives known to be associated with increased risk of inherited breast cancer susceptibility variant. May include criteria such as:
2 or more relatives with breast or ovarian cancer
breast cancer occurring before age 50 years
a family history of both breast and ovarian cancer
one or more relatives with 2 cancers (breast and ovarian cancer or 2 independent breast cancers)
male relatives with breast cancer
Source: ACS
FAMILY HISTORY includes >= 2 first- or second- degree relatives with breast cancer
OR
FAMILY HISTORY includes >= 2 first- or second- degree relatives with ovarian cancer
OR
FAMILY HISTORY includes >= 1 first- or second- degree relatives with breast cancer diagnosed <= 50 years old
OR
FAMILY HISTORY includes at least one first- or second- degree relative with breast AND at least one relative wth ovarian cancer
OR
FAMILY HISTORY includes >= 1 first- or second- degree relative with both breast and ovarian cancer
OR
FAMILY HISTORY includes >= 1 first- or second- degree relative with 2 independent breast cancers
OR
FAMILY HISTORY includes >= 1 first- or second- degree male relative with breast cancer

Approved for Public Release, Distribution Unlimited.
Public Release Case Number 24-2711
Copyright ©2024 The MITRE Corporation. All rights reserved.